Drugs / Atropine
Atropine
also known as
atropine sulfate · atropine sulphate · Alleance · ATR · Atroject · Atropen · Atrophate · Atropine (autoinjector) · +35 more
Other / unclassified targets CHRM1, CHRM2, CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Atropine sulfate FGK | — | 2025-11-21 | europa.eu ↗ |
| Approved | EU (EMA) | Ryjunea | — | 2025-06-02 | europa.eu ↗ |
| Label expansion | US (FDA) | ATROPEN | — | 2003-06-19 | fda.gov ↗ |
| Approved | US (FDA) | LOMOTIL | — | 1960-09-15 | fda.gov ↗ |
Trials 107 · started per year
today
US approved 1960
EU approved 2025
1
1
2
3
1
2
4
1
2
3
3
2
3
3
5
2
6
8
4
7
9
12
7
4
12
19591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT05164367 | Oct 2022 → Jun 2023 | cerebral palsy | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT05199597 | May → Jun 2022 | myopia | Ohio State University | Completed | No outcome recorded |
| Phase 0 | NCT03972683 | Apr 2019 → Jul 2021 | — | Colorado State University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03508817 | Dec 2018 → Jan 2022 | myopia | Sultan Qaboos University | Unknown | No outcome recorded |
| Phase 0 | NCT02823665 | Jul 2015 → Aug 2026 overdue | postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT00992901 | Oct 2009 → Aug 2026 overdue | hypoglycemia, postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT00689208 | May 2007 → Oct 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 18 trials · 1 met primary | ||||||
| Phase 1 | NCT05855018 | May → Jun 2023 | — | Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1 | NCT05481489 | Feb → Mar 2023 | myopia | Laboratorios Sophia S.A de C.V. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05470881 | Aug → Dec 2022 | myopia | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT07674966 | Mar → Oct 2022 | myopia | University of California, Berkeley | Completed | No outcome recorded |
| Phase 1 | NCT01951729 | Mar 2013 → May 2015 | prediabetes syndrome | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00932256 | Oct 2009 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00457717 | Jul 2005 → Jul 2006 | myopia | China Medical University, China | Completed | Met primary |
| Phase 1 | NCT00251602 | Mar 2003 → Aug 2012 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07449247 | Mar 2026 → Jun 2027 expected | myopia | Tianjin Medical University Eye Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06523504 | Feb 2024 → Mar 2026 overdue | myopia | Ruihua Wei | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03593044 | Jul 2018 → Jan 2019 | myopia | Jeffrey J. Walline, OD PhD | Completed | No outcome recorded |
| Phase 213 trials · 1 met primary | ||||||
| Phase 2 | NCT07816224 | Sep → Nov 2026 expected | excessive tearing | Rehan Ahmed | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07367178 | Jul 2026 → Jun 2027 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | MedSIR | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07676981 | Jun → Jul 2026 | epiphora due to excess lacrimation | Rehan Ahmed | Completed | No outcome recorded |
| Phase 2 | NCT06765603 | Feb 2025 → Dec 2028 expected | myopia | Singapore National Eye Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06200194 | Oct 2024 → Jul 2026 overdue | myopia | National Yang Ming Chiao Tung University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06174935 | Jan → Jun 2024 | vitreous disorder | Jeanette Du | Unknown | No outcome recorded |
| Phase 2 | NCT05815784 | May 2023 → Mar 2026 overdue | myopia | Ann & Robert H Lurie Children's Hospital of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT04391361 | Nov 2020 → Sep 2023 | amyotrophic lateral sclerosis | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03911271 | May 2019 → Apr 2024 | myopia | Line Kessel | Completed | No outcome recorded |
| Phase 2 | NCT03690089 | Apr 2019 → Feb 2024 overdue | myopia | Belfast Health and Social Care Trust | Active not recruiting | Met primary |
| Phase 2 | NCT02082054 | Mar → May 2014 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00121524 | Jan 2003 → May 2008 | cardiac arrest | Petter Andreas Steen | Completed | No outcome recorded |
| Phase 2 | NCT00431392 | Sep 2001 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07164092 | Sep 2025 → Sep 2027 expected | myopia | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03865160 | Oct 2021 → Nov 2025 overdue | myopia | University Eye Hospital, Freiburg | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04173780 | Feb 2020 → May 2024 | myopia | University Hospital, Strasbourg, France | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00371124 | Mar 2006 → ? | myopia | Singapore National Eye Centre | Unknown | No outcome recorded |
| Phase 319 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT07095894 | Jun 2026 → Dec 2028 expected | myopia | Jaeb Center for Health Research | Recruiting | No outcome recorded |
| Phase 3 | NCT07567040 | May 2026 → May 2028 expected | myopia | Ohio State University | Recruiting | No outcome recorded |
| Phase 3 | NCT07028827 | Sep 2025 → Dec 2027 expected | myopia | Ocus Innovation Ireland Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06697522 | Jun → Oct 2023 | myopia | Ocumension Therapeutics (Suzhou) Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05529056 | May 2022 → Jun 2023 | myopia | LitePharmTech Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT06209281 | May 2022 → Aug 2023 overdue | myopia | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04910477 | Jun → Sep 2021 | headache disorder | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04770610 | Apr 2021 → Mar 2027 expected | myopia | Ocumension (Hong Kong) Limited | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04338373 | Feb 2020 → Aug 2021 | myopia | The V.P. Vyhodcev Eye Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03942419 | Jun 2019 → Oct 2024 | myopia | Eyenovia Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03918915 | Apr 2019 → May 2024 | myopia | Sydnexis, Inc. | Completed | Met primary |
| Phase 3 | NCT03334253 | Jun 2018 → Apr 2022 | myopia | Jaeb Center for Health Research | Completed | Missed primary |
| Phase 3 | NCT03350620 | Nov 2017 → Sep 2022 | myopia | Vyluma, Inc. | Completed | Missed primary |
| Phase 3 | NCT02870478 | Jul 2016 → Nov 2019 | myopia | University of California, Berkeley | Completed | No outcome recorded |
| Phase 3 | NCT02194088 | Apr → Nov 2014 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01293201 | Mar → Jun 2011 | seasonal allergic rhinitis | Magna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00583323 | Feb 2003 → Sep 2005 | lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00094692 | Oct 2002 → Dec 2005 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 3 | NCT00001864 | May 1999 → Nov 2001 | amblyopia, anisometropia, strabismus | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 424 trials · 1 met primary | ||||||
| Phase 4 | NCT07851870 | Feb → Mar 2026 | — | Universitas Indonesia | Completed | No outcome recorded |
| Phase 4 | NCT07434635 | Feb 2026 → Feb 2028 expected | eye disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT06450132 | Aug 2024 → Jun 2026 overdue | myopia | Ohio State University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05892913 | Jul → Oct 2023 | pregnancy disorder | Abant Izzet Baysal University | Completed | No outcome recorded |
| Phase 4 | NCT07406399 | Jun 2023 → Nov 2025 | contact lens corneal edema, myopia | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05065424 | Apr 2022 → Mar 2026 | newborn respiratory distress syndrome | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05448989 | Jan 2022 → Dec 2023 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT05357326 | Jul 2021 → Jul 2023 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | Met primary |
| Phase 4 | NCT04641702 | Mar 2021 → Dec 2028 expected | achalasia | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT05449015 | Dec 2020 → Mar 2023 | cycloplegia, myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT03984526 | Jun 2019 → Sep 2020 | — | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03949101 | May 2019 → May 2021 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| Phase 4 | NCT03638726 | Sep 2018 → Mar 2019 | cataract | Dar El Oyoun Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03544827 | May 2018 → Feb 2019 | myopia | State University of New York College of Optometry | Completed | No outcome recorded |
| Phase 4 | NCT03158142 | Mar → Nov 2017 | myopia | State University of New York College of Optometry | Completed | No outcome recorded |
| Phase 4 | NCT02769325 | May 2016 → May 2017 | — | Clinica Santa Maria | Unknown | No outcome recorded |
| Phase 4 | NCT02522858 | Aug 2015 → Jan 2016 | — | Sira Bang | Completed | No outcome recorded |
| Phase 4 | NCT01819064 | Feb → Jul 2013 | cardiac rhythm disease | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT01845636 | Aug 2012 → Mar 2016 | cognitive impairment with or without cerebellar ataxia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02186132 | Mar 2012 → Feb 2013 | curariform drugs toxicity | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00834470 | Aug 2008 → Dec 2010 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00921102 | May 2007 → Feb 2008 | — | University of Parma | Completed | No outcome recorded |
| Phase 4 | NCT00541177 | Apr 2007 → Mar 2008 | myopia | Min-Sheng General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00094614 | Jun 2002 → Apr 2003 | amblyopia | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase not applicable29 trials · 2 met primary · 1 missed | ||||||
| — | NCT07846787 | Sep 2026 → Aug 2028 expected | myopia | Ruihua Wei | Not yet recruiting | No outcome recorded |
| — | NCT07537166 | Apr → Dec 2026 expected | — | China Medical University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT07475585 | Mar 2026 → Jul 2027 expected | myopia | Fangbiao Tao | Not yet recruiting | No outcome recorded |
| — | NCT07364370 | Feb 2026 → Aug 2027 expected | early-onset non-syndromic cataract, myopia | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT07176949 | Jun 2025 → Jun 2027 expected | myopia | Shanghai Eye Disease Prevention and Treatment Center | Recruiting | No outcome recorded |
| — | NCT06667037 | Sep 2024 → Dec 2026 expected | myopia | Zhongshan Ophthalmic Center, Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06358755 | Jul 2024 → Apr 2026 overdue | myopia | The Hong Kong Polytechnic University | Active not recruiting | No outcome recorded |
| — | NCT05379855 | Mar 2024 → Feb 2027 expected | exotropia, myopia | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT06071260 | Dec 2023 | myopia | He Eye Hospital | Unknown | No outcome recorded |
| — | NCT06034379 | Oct 2023 → Dec 2025 overdue | myopia | Kubota Vision Inc. | Recruiting | No outcome recorded |
| — | NCT06034366 | Oct 2023 → May 2025 | myopia | He Eye Hospital | Unknown | No outcome recorded |
| — | NCT06727019 | Apr → Sep 2023 | myopia | Beijing Tongren Hospital | Completed | No outcome recorded |
| — | NCT05939882 | Apr 2023 → Apr 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| — | NCT05597163 | Jan 2023 → Nov 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Unknown | No outcome recorded |
| — | NCT05560542 | Oct 2022 → Mar 2025 | poisoning | Assiut University | Completed | No outcome recorded |
| — | NCT04699357 | Jul 2021 → Aug 2024 | myopia | Shanghai Eye Disease Prevention and Treatment Center | Completed | No outcome recorded |
| — | NCT04625088 | Mar → Aug 2021 | — | SciMar Ltd. | Completed | No outcome recorded |
| — | NCT04777383 | Apr 2019 → Oct 2021 | vascular disorder | University Hospital, Linkoeping | Terminated | No outcome recorded |
| — | NCT03374306 | Feb 2018 → Dec 2019 | myopia | The Hong Kong Polytechnic University | Completed | No outcome recorded |
| — | NCT02955927 | Nov 2016 → May 2021 | myopia | The Hong Kong Polytechnic University | Completed | Met primary |
| — | NCT02927223 | Oct 2016 → Feb 2019 | catecholaminergic polymorphic ventricular tachycardia | Vanderbilt University | Completed | Met primary |
| — | NCT03312257 | Jul 2016 → Jun 2020 | refractive error | Jenny Jones | Completed | Missed primary |
| — | NCT03839888 | Jan → Dec 2015 | myopia | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Completed | No outcome recorded |
| — | NCT03402100 | Oct 2014 → Dec 2019 | drug pseudoallergy, myopia | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT02130167 | Aug 2012 → Jul 2017 | myopia | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT01464489 | May → Sep 2011 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| — | NCT02055378 | Jan 2011 → Dec 2012 | myopia | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Completed | No outcome recorded |
| — | NCT00320892 | Jan 2007 → Dec 2009 | — | Soroka University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00328900 | Jan 2006 → ? | hemorrhoid, ulcer of anus and rectum | Rikshospitalet University Hospital | Unknown | No outcome recorded |
| Comparator or background therapy136 trials | ||||||
| Phase 0 | NCT03328312 Comparator | Dec 2017 → Mar 2018 | curariform drugs toxicity | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 1 | NCT06787638 Comparator | Jan 2025 → Jan 2026 overdue | — | Aswan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06982092 Comparator | Aug 2024 → Jan 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06029530 Comparator | Jan → Aug 2024 | myopia | Ohio State University | Withdrawn | No outcome recorded |
| Phase 1 | NCT04290039 Comparator | Jan → Feb 2020 | poisoning | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
| Show all 136 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | Sydnexis, Inc. | Regulatory Sydnexis Announces FDA Advisory Committee Meeting Date to Review NDA for SYD-101 for Pediatric Progressive Myopia sydnexis.com ↗
Sydnexis, Inc., a clinical-stage pharmaceutical company developing SYD-101, a novel low-dose atropine formulation for the treatment of pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Advisory Committee meeting, including an Open Public Hearing, for October 30, 2026, to review the New Drug Application (NDA) for SYD-101. |
| 2026-07-13 | Sydnexis, Inc. | Regulatory Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia sydnexis.com ↗
While the date for the meeting has not been set, the FDA has indicated that the Advisory Committee will be asked to discuss various aspects of the Company’s application, including findings from the Phase 3 STAR study. |
| 2026-03-23 | Sydnexis, Inc. | Results Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting sydnexis.com ↗
SYD-101 0.01% successfully met both the primary endpoint (p=0.0226) and the key secondary endpoint. |
| 2025-11-06 | Sydnexis, Inc. | Regulatory Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia sydnexis.com ↗
“We are thrilled that the MHRA has granted approval of Ryjunea ® to Santen, marking another important milestone in bringing this innovative therapy to even more patients in need,” said Perry Sternberg, Chief Executive Officer of Sydnexis. |
| 2025-11-04 | Sydnexis, Inc. | Results Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025 sydnexis.com ↗ |
| 2025-10-31 | Sydnexis, Inc. | Results Sydnexis Wins Poster Session at Vision by Design 2025: Effect of pH and BAK on Pupil Dilation Following Low-dose Atropine Administration in Dutch Belted Rabbits sydnexis.com ↗
Results showed that a neutral pH formulation containing BAK produced greater and more sustained pupil dilation compared to an acidified, BAK-free formulation, suggesting that these variables can significantly influence drug bioavailability and efficacy in low-dose atropine therapies |
| 2025-10-23 | Sydnexis, Inc. | Regulatory Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression sydnexis.com ↗
The FDA acknowledged in the complete response letter (CRL) that this primary endpoint was met but stated its view that the data do not support the effectiveness of low-dose atropine in children with myopia. |
| 2025-06-05 | Sydnexis, Inc. | Regulatory Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia sydnexis.com ↗
Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. |
| 2025-04-01 | Sydnexis, Inc. | Regulatory Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia sydnexis.com ↗ |
| 2025-03-31 | Santen Gmbh | Regulatory Santen Receives Positive CHMP Opinion in Europe for Ryjunea🄬 for slowing the progression of paediatric myopia santen.com ↗
March 31, 2025 – Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for Ryjunea🄬 (development code: STN1012701). |
| 2025-03-11 | Sydnexis, Inc. | Regulatory Sydnexis Announces FDA Acceptance of New Drug Application and PDUFA date for SYD-101, for the Treatment of Progression of Pediatric Myopia. sydnexis.com ↗ |
| 2023-07-20 | Ocumension Therapeutics (Shanghai) Co., Ltd | Regulatory 欧康维视低浓度阿托品OT-101-S（液液双腔）国内III期临床试验申请获受理 ocumension.com ↗
北京时间2023年7月20日 欧康维视生物宣布核心自研产品OT-101-S（0.01%及0.05% 硫酸阿托品滴眼液 ）在国内的III期临床试验申请获CDE受理，用于延缓儿童近视进展。 |
| 2021-08-02 | Ocumension Therapeutics (Shanghai) Co., Ltd | Regulatory 再下一城！欧康维视低浓度阿托品OT-101在英国获得III期临床试验批件 ocumension.com ↗
北京时间2021年8月2日，欧康维视生物宣布核心自研产品 OT-101（0.01%硫酸阿托品滴眼液）在英国已获英国药品及保健品管理局(Medicines and Healthcare products Regulatory Agency)同意开展III期临床试验。 |
| 2021-02-22 | Ocumension Therapeutics (Shanghai) Co., Ltd | Regulatory 欧康维视低浓度硫酸阿托品滴眼液OT-101获得美国FDA临床Ⅲ期试验批件 ocumension.com ↗
北京时间2021年2月22日，欧康维视宣布其自主研发的治疗儿童青少年近视进展的产品OT-101（0.01%硫酸阿托品滴眼液）获得美国FDA批准开展Ⅲ期临床试验，之后欧州与中国也将加入此项国际多中心Ⅲ期临床试验。 |
All press releases naming this drug 16 releases
Evidence & citations 50 cited values
Every value below carries the sentence it was read from. 247 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atropine | “The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine...” NCT01293201 ↗220“Neostigmine (0.03 mg/kg) combined with atropine (0.015 mg/kg) is administered intravenously for reversal of rocuronium-induced neuromuscular blockade at the end of unilateral...” NCT07309393 ↗ “Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries: A Randomized...” NCT06729047 ↗ “To assess the safety and efficacy of NVK002 (Vyluma), a novel, preservative-free, 0.01% and 0.02% low-dose atropine formulation for treating myopia progression.” PMID 37261839 ↗ Oct 2023 “Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch” NCT04258007 ↗ “patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.” NCT04566796 ↗ “The CHAMP UK study is investigating a type of eye drop called atropine that might help to stop myopia getting worse as children get older.” NCT03690089 ↗ “When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).” NCT06678451 ↗ “The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over” NCT01809886 ↗ “Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.” NCT00932256 ↗ “a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.” NCT06436768 ↗ |
| Known as | Alleance | “Alleance®. Atropine sulfate 0.01%. Ophthalmic solution.” NCT06389110 ↗ |
| Known as | ATR | “atropine (ATR) + clamp (CLA) + MSF” PMID 26492921 ↗ Oct 2015 |
| Known as | Atroject | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropen | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atrophate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine component of atnaa | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine component of duodote | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine gel, mucoadhesive atropine gel | “Atropine gel, mucoadhesive atropine gel” NCT05164367 ↗ |
| Known as | atropine sulfate | “OBJECTIVE: To compare weekend atropine sulfate use augmented by a plano lens for the sound eye with weekend atropine use alone for moderate amblyopia in children aged 3 years...” PMID 19139333 ↗ Jan 200930“Topical atropine sulfate ophthalmic solution 0.01% administered as one drop in each eye once daily at bedtime for 18 months for control of myopia progression in children.” NCT07626892 ↗ “Atropine sulfate ophthalmic solution (0.005% w/v) for the Treatment of Symptoms of Epiphora” NCT07816224 ↗ “three low-concentration atropine sulfate eye drops (0.01%, 0.025% and 0.05%)” NCT05597163 ↗ “Atropine Sulfate 0.05% Oph Soln compounded at the pharmacy” NCT07567040 ↗ “Two drops of 0.01% atropine sulfate solution” NCT07674966 ↗ “Atropine sulfate 0.01%, ophthalmic solution.” NCT06389110 ↗ “0.02% Atropine Sulfate Eye Drops” NCT07846787 ↗ “OT-101 (Atropine Sulfate 0.01%)” NCT04770610 ↗ “Drug: Atropine sulfate 0.01%” NCT03140358 ↗ “Atropine sulfate gel (0.01%)” NCT05164367 ↗ |
| Known as | Atropine sulfate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate ansyr plastic syringe | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of colonaid | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of di-atro | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of enlon-plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lo-trol | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of logen | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lomanate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lomotil | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of lonox | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of low-quel | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate component of motofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate injection | “Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for...” NCT04290039 ↗ |
| Known as | Atropine sulfate lifeshield abboject syringe | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropine sulfate ophthalmic solution | “Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia.” NCT04290039 ↗ |
| Known as | atropine sulphate | “Hyperbaric bupivacaine 10 mg + preservative-free morphine 100 µg + atropine sulphate 100 µg in 4 mL, single intrathecal injection before induction” NCT07851870 ↗5“with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml” NCT05137288 ↗ “The atropine eye drops contain 0.01% atropine sulphate.” NCT03690089 ↗ “Atropine Sulphate 0.025% w/v Eye Drops” NCT07329777 ↗ |
| Known as | atropinehydrochloride | “Patients scheduled for PEI were randomized 1:1 to receive 0.5 mg atropinehydrochloride or placebo in a double-blind randomized placebo-controlled trial.” PMID 19018977 ↗ Oct 2008 |
| Known as | Atropini sulfas | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropinum Sulfuricum WZF | “atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously” NCT06609993 ↗ |
| Known as | Atropinum sulphuricum | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropisol | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Atropt | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Dl-hyoscyamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | Isopto atropine | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | NSC-26671 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | NSC-755889 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517712 ↗ |
| Known as | OT-101 | “OT-101 (Atropine Sulfate 0.01%)” NCT04770610 ↗ |
| Known as | PRO-201 | “Evaluation of the safety and tolerability of PRO-201 (0.01% sulfate atropine) after its instillation on the ocular surface of healthy volunteers through the following...” NCT05470881 ↗ |
| Known as | SYD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03918915 ↗ |
| Known as | Xingqi Meioupin | “Initial treatment: 1 time per night, apply 0.01% atropine eye drops to both eyes (brand name: Xingqi Meioupin, Xingqi Pharmaceutical, 30 drops per box).” NCT07475585 ↗ |
| Action | Inhibit | “acts as an antagonist on the muscarinic receptors of the sweat glands and inhibits their secretion” NCT00328900 ↗3“Muscarinic acetylcholine receptor M1 antagonist” CHEMBL517712 ↗ “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL517712 ↗ “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL517712 ↗ |
| Modality | Other / unclassified | “Atropine is an anticholinergic agent” NCT05658380 ↗ |
| Route | Intravenous | “Atropine 3 mg iv in initial systole” NCT00121524 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL517712 ↗ |
| Target | CHRM2 | “Muscarinic acetylcholine receptor M2 antagonist” CHEMBL517712 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL517712 ↗ |